Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, will be part of the upcoming third annual Psychedelic Therapeutics and Drug Development Conference. The company announced that vice president of R&D James Kuo, MD, will be presenting at the conference, which is scheduled to be held on May 15–16, 2023, in Burlington, California. Titled “The Ketamine Endgame,” Kuo’s presentation will include key information about ketamine and Silo Pharma’s involvement in the space; his presentation is scheduled to begin at 1:05 p.m. PDT. According to the company, three of Silo Pharma’s five novel drug candidates currently under development include ketamine as a primary therapeutic agent. The Psychedelic Therapeutics and Drug Development Conference is designed to gather leaders and experts in an array of sectors, including research, academia, industry, nonprofit sector and government. Agenda items will include discussions about the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need.
To view the full press release, visit https://ibn.fm/MWKMK
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications for people suffering from indications such as Alzheimer’s disease, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
